{"protocolSection":{"identificationModule":{"nctId":"NCT02392507","orgStudyIdInfo":{"id":"15529"},"secondaryIdInfos":[{"id":"I4X-MC-JFCP","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC","officialTitle":"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)"},"statusModule":{"statusVerifiedDate":"2019-11-15","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-10-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-01-29","type":"ACTUAL"},"completionDateStruct":{"date":"2019-11-06","type":"ACTUAL"},"studyFirstSubmitDate":"2015-03-16","studyFirstSubmitQcDate":"2015-03-16","studyFirstPostDateStruct":{"date":"2015-03-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-01-18","resultsFirstSubmitQcDate":"2019-01-18","resultsFirstPostDateStruct":{"date":"2019-02-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-10-30","lastUpdatePostDateStruct":{"date":"2020-11-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"},"collaborators":[{"name":"Celgene","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer."},"conditionsModule":{"conditions":["Carcinoma, Non-Small Cell Lung Cancer (NSCLC)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":54,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Necitumumab + Nab-Paclitaxel + Carboplatin","type":"EXPERIMENTAL","description":"Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg\\*min/mL) on day 1 of each cycle, for a maximum of 4 cycles.\n\nMaintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Necitumumab","Drug: Nab-Paclitaxel","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Necitumumab","description":"Administered IV","armGroupLabels":["Necitumumab + Nab-Paclitaxel + Carboplatin"],"otherNames":["LY3012211","IMC-11F8"]},{"type":"DRUG","name":"Nab-Paclitaxel","description":"Administered IV","armGroupLabels":["Necitumumab + Nab-Paclitaxel + Carboplatin"],"otherNames":["Abraxane"]},{"type":"DRUG","name":"Carboplatin","description":"Administered IV","armGroupLabels":["Necitumumab + Nab-Paclitaxel + Carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])","description":"ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","timeFrame":"From Date of Randomization to Objective Disease Progression (Up to 18 Months)"}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS)","description":"PFS defined as time from date of randomization until first radiographic documentation of measured PD defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 mm,or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization,regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis,the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.","timeFrame":"From Date of Randomization to Measured Progressive Disease or Death Due to Any Cause (Up to 18 Months)"},{"measure":"Overall Survival (OS)","description":"OS defined as the time from the date of randomization to the date of death due to any cause. Participants who are alive at the time of study completion or are lost to follow-up will be censored at the time they were last known to be alive.","timeFrame":"From Date of Randomization until Death Due to Any Cause (Up to 18 Months)"},{"measure":"Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])","description":"Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","timeFrame":"From Date of Randomization to Objective Disease Progression or Start of New Anticancer Therapy (Up to 18 Months)"},{"measure":"Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab, Nab-Paclitaxel, and Carboplatin","description":"The Cmin is the minimum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.","timeFrame":"Cycle 3 and cycle 4: predose"},{"measure":"PK: Maximum Concentration (Cmax) of Necitumumab, Nab-Paclitaxel, and Carboplatin","description":"The Cmax is the maximum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.","timeFrame":"Cycle 1, 3 and 4: predose and <15minutes (min) post end-of-infusion"},{"measure":"Immunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab","description":"A participant was considered to have an anti-drug antibody response if anti-drug antibodies (ADA) were detected at any time point.","timeFrame":"Predose Cycle 1 Through Short Term Follow Up (Up To 18 Months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have histologically or cytologically confirmed squamous NSCLC.\n* Have stage IV disease at the time of study entry (American Joint Committee on Cancer \\[AJCC\\] Staging Manual, 7th edition).\n* Have measurable disease at the time of study enrollment as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).\n* Have tumor tissue available for biomarker analysis.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Have adequate organ functions.\n\nExclusion Criteria:\n\n* Are currently enrolled in another clinical trial.\n* Have received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or VEGF receptor.\n* Have received previous chemotherapy for advanced NSCLC. Participants who have received adjuvant or neoadjuvant chemotherapy are eligible if the last administration of the prior regimens occurred at least 1 year prior to study entry.\n* Have undergone major surgery or received any investigational therapy in the 4 weeks prior to study entry.\n* Have undergone systemic radiotherapy within 4 weeks prior to study entry, or focal radiotherapy within 2 weeks prior to study entry.\n* Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required).\n* Have a history of arterial or venous embolism within 6 months prior to study entry.\n* Have clinical evidence of concomitant infectious conditions.\n* Have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.\n* Are pregnant or breastfeeding.\n* Have a known history of drug abuse.\n* Have a concurrent active malignancy. Participants with a history of malignancy are eligible provided the participant has been disease-free for ≥3 years, with the following exception: Participants with adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancer that in the judgment of the investigator and Lilly clinical research physician/designee may not affect the interpretation of results (for example, prostate, bladder) are eligible.\n* Have discontinued investigational product or non approved use of a drug or device from a clinical trial within 30 days before the first day of study treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Florida Hospital Cancer Institute","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Click here for more information about this study: A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC","url":"http://www.lillytrialguide.com/en-US/studies/non-small-cell%20lung%20cancer/JFCP#?postal="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants with known best overall response and off study treatment were considered to be completed.","groups":[{"id":"FG000","title":"Necitumumab + Nab-Paclitaxel + Carboplatin","description":"Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg\\*min/mL) on day 1 of each cycle, for a maximum of 4 cycles.\n\nMaintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"periods":[{"title":"Induction Regimen","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"54"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"54"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"47"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"On Study Treatment at Study Conclusion","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]},{"title":"Maintenance Regimen","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"After induction regimen participants with disease response are eligible for maintenance regimen.","numSubjects":"34"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"32"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"On Study Treatment at Study Conclusion","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants who received at least 1 dose of study drug.","groups":[{"id":"BG000","title":"Necitumumab + Nab-Paclitaxel + Carboplatin","description":"Induction: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 mg/m² on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC 6 mg\\*min/mL on day 1 of each cycle, for a maximum of 4 cycles.\n\nMaintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"54"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.96","spread":"7.48"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"12"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"42"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"50"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"53"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}]},{"title":"Greece","categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])","description":"ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","populationDescription":"All randomized participants who received at least 1 dose of study drug and who had a complete radiographic assessment at baseline and at least 1 complete radiographic assessment post-baseline.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Date of Randomization to Objective Disease Progression (Up to 18 Months)","groups":[{"id":"OG000","title":"Necitumumab + Nab-Paclitaxel + Carboplatin","description":"Induction: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 mg/m² on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC 6 mg\\*min/mL on day 1 of each cycle, for a maximum of 4 cycles.\n\nMaintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS defined as time from date of randomization until first radiographic documentation of measured PD defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 mm,or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization,regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis,the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.","populationDescription":"All randomized participants who received at least 1 dose of study drug. Censored participants = 15.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From Date of Randomization to Measured Progressive Disease or Death Due to Any Cause (Up to 18 Months)","groups":[{"id":"OG000","title":"Necitumumab + Nab-Paclitaxel + Carboplatin","description":"Induction: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 mg/m² on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC 6 mg\\*min/mL on day 1 of each cycle, for a maximum of 4 cycles.\n\nMaintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.59","lowerLimit":"4.24","upperLimit":"7.69"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS defined as the time from the date of randomization to the date of death due to any cause. Participants who are alive at the time of study completion or are lost to follow-up will be censored at the time they were last known to be alive.","populationDescription":"All randomized participants who received at least 1 dose of study drug. Censored participants = 35.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From Date of Randomization until Death Due to Any Cause (Up to 18 Months)","groups":[{"id":"OG000","title":"Necitumumab + Nab-Paclitaxel + Carboplatin","description":"Induction: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 mg/m² on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC 6 mg\\*min/mL on day 1 of each cycle, for a maximum of 4 cycles.\n\nMaintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.54","lowerLimit":"10.18","upperLimit":"NA","comment":"The upper limit of the 95% CI was not calculated due to the high censoring rate."}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])","description":"Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","populationDescription":"All randomized participants who received at least 1 dose of study drug and who had a complete radiographic assessment at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Date of Randomization to Objective Disease Progression or Start of New Anticancer Therapy (Up to 18 Months)","groups":[{"id":"OG000","title":"Necitumumab + Nab-Paclitaxel + Carboplatin","description":"Induction: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 mg/m² on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC 6 mg\\*min/mL on day 1 of each cycle, for a maximum of 4 cycles.\n\nMaintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.4"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab, Nab-Paclitaxel, and Carboplatin","description":"The Cmin is the minimum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram per milliliter (ng/mL)","timeFrame":"Cycle 3 and cycle 4: predose","groups":[{"id":"OG000","title":"Necitumumab","description":"Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle (3 week cycles)."},{"id":"OG001","title":"Carboplatin","description":"Carboplatin administered IV at a concentration of AUC 6 mg\\*min/mL on day 1 of each cycle, for a maximum of 4 cycles."},{"id":"OG002","title":"Paclitaxel","description":"Nab-paclitaxel administered IV at 100 mg/m² on day 1, 8 and 15 of each cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"3"}]}],"classes":[{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":"86.9"},{"groupId":"OG001","value":"0.131","spread":"36"},{"groupId":"OG002","value":"33.6","spread":"393"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":"74.9"},{"groupId":"OG001","value":"0.209","spread":"197"},{"groupId":"OG002","value":"107","spread":"313"}]}]}]},{"type":"SECONDARY","title":"PK: Maximum Concentration (Cmax) of Necitumumab, Nab-Paclitaxel, and Carboplatin","description":"The Cmax is the maximum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Cycle 1, 3 and 4: predose and <15minutes (min) post end-of-infusion","groups":[{"id":"OG000","title":"Necitumumab","description":"Necitumumab administered IV 800 mg on day 1 and 8 of each cycle (3 week cycles)."},{"id":"OG001","title":"Carboplatin","description":"Carboplatin administered IV at a concentration of AUC 6 mg\\*min/mL on day 1 of each cycle, for a maximum of 4 cycles."},{"id":"OG002","title":"Paclitaxel","description":"Nab-paclitaxel administered IV at 100 mg/m² on day 1, 8 and 15 of each cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"37"}]}],"classes":[{"title":"Cycle 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":"27.1"},{"groupId":"OG001","value":"16.4","spread":"22"},{"groupId":"OG002","value":"343","spread":"81.2"}]}]},{"title":"Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"291","spread":"46.5"},{"groupId":"OG001","value":"16","spread":"26.4"},{"groupId":"OG002","value":"284","spread":"73"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"277","spread":"42.5"},{"groupId":"OG001","value":"10.5","spread":"160"},{"groupId":"OG002","value":"221","spread":"77.6"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab","description":"A participant was considered to have an anti-drug antibody response if anti-drug antibodies (ADA) were detected at any time point.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had evaluable data for antibodies.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Predose Cycle 1 Through Short Term Follow Up (Up To 18 Months)","groups":[{"id":"OG000","title":"Necitumumab + Nab-Paclitaxel + Carboplatin","description":"Induction: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 mg/m² on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC 6 mg\\*min/mL on day 1 of each cycle, for a maximum of 4 cycles.\n\nMaintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline Up to 49 Months","description":"All randomized participants who received at least 1 dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.","eventGroups":[{"id":"EG000","title":"Necitumumab + Nab-paclitaxel + Carboplatin: Induction Phase","description":"Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 mg/m² on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC 6 mg\\*min/mL on day 1 of each cycle, for a maximum of 4 cycles. Participants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":3,"deathsNumAtRisk":54,"seriousNumAffected":18,"seriousNumAtRisk":54,"otherNumAffected":54,"otherNumAtRisk":54},{"id":"EG001","title":"Necitumumab + Nab-paclitaxel: Maintenance Phase","description":"Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles). Participants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":1,"deathsNumAtRisk":34,"seriousNumAffected":5,"seriousNumAtRisk":34,"otherNumAffected":31,"otherNumAtRisk":34}],"seriousEvents":[{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Gastrointestinal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Small intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":34}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":101,"numAffected":34,"numAtRisk":54},{"groupId":"EG001","numEvents":27,"numAffected":15,"numAtRisk":34}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":18,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":19,"numAtRisk":54},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":34}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":16,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":34}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":10,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":34}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":8,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":77,"numAffected":32,"numAtRisk":54},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":34}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":34}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":34}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":34}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":54},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":34}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Vaginal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":34}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":34}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":85,"numAffected":32,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":17,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":12,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":13,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":7,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":10,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":34}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":10,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":26,"numAtRisk":54},{"groupId":"EG001","numEvents":25,"numAffected":7,"numAtRisk":34}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":12,"numAtRisk":54},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":34}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":34}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":54},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":34}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":7,"numAffected":2,"numAtRisk":34}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":54},{"groupId":"EG001","numEvents":17,"numAffected":9,"numAtRisk":34}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":34}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":34}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":11,"numAtRisk":54},{"groupId":"EG001","numEvents":5,"numAffected":1,"numAtRisk":34}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":54},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":34}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":16,"numAtRisk":54},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":34}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":54},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":34}]},{"term":"Nail discolouration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":54},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":34}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":54},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":34}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":20,"numAtRisk":54},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":34}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":54},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":34}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"clinicaltrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-09-25","uploadDate":"2018-11-15T01:30","filename":"Prot_000.pdf","size":1138334},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2015-08-14","uploadDate":"2018-11-15T01:40","filename":"SAP_001.pdf","size":556676}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Germany","Greece","Spain"]},"conditionBrowseModule":{"meshes":[{"id":"D002277","term":"Carcinoma"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C527969","term":"necitumumab"},{"id":"C520255","term":"130-nm albumin-bound paclitaxel"},{"id":"D000068196","term":"Albumin-Bound Paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D017239","term":"Paclitaxel"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D000418","term":"Albumins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}